B Schmitz-Drager

Summary

Country: Germany

Publications

  1. doi [Metabolic syndrome and prostate cancer]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth, Deutschland
    Urologe A 52:842-6. 2013
  2. doi Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration
    Bernd J Schmitz-Drager
    Urologie, EuromedClinic Urologie, Fürth, Germany
    Urol Int 90:329-33. 2013
  3. doi [Chemoprevention of prostate cancer - a plea]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Fürth, Deutschland
    Aktuelle Urol 43:157-61. 2012
  4. doi [Prevention of uro-oncological diseases]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth, Deutschland
    Urologe A 51:727-36. 2012
  5. doi [Secondary and tertiary prevention of urological tumors]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763, Fürth, Deutschland
    Urologe A 50:1283-7. 2011
  6. doi [Primary prevention of urologic tumors: prostate cancer]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763, Fürth, Deutschland
    Urologe A 50:1271-2, 1274-5. 2011
  7. doi [Role of immunocytology in the evaluation of patients with painless gross hematuria]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763, Fürth, Germany
    Urologe A 49:741-6. 2010
  8. doi [Risks and prevention of prostate cancer. Commentary on the new S3 guideline]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth
    Urologe A 49:233-7. 2010
  9. ncbi Immunocytology in the assessment of patients with asymptomatic hematuria
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth, Germany
    World J Urol 26:31-7. 2008
  10. ncbi [Analyses of the role of immunocytology in the differential diagnosis of patients with asymptomatic microhematuria]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763, Fürth
    Urologe A 47:190-4. 2008

Detail Information

Publications18

  1. doi [Metabolic syndrome and prostate cancer]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth, Deutschland
    Urologe A 52:842-6. 2013
    ..Based on this evolution prevention, early detection and sustainable therapy represent an important clinical challenge to modern urologists active in urooncology...
  2. doi Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration
    Bernd J Schmitz-Drager
    Urologie, EuromedClinic Urologie, Fürth, Germany
    Urol Int 90:329-33. 2013
    ..This improved efficacy was linked to an increase of side effects...
  3. doi [Chemoprevention of prostate cancer - a plea]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Fürth, Deutschland
    Aktuelle Urol 43:157-61. 2012
    ..This review investigates potential risks and benefits of chemoprevention including a consideration of health economical aspects. The authors conclude that the options of chemoprevention should be investigated in an open and unbiased way...
  4. doi [Prevention of uro-oncological diseases]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth, Deutschland
    Urologe A 51:727-36. 2012
    ..However, translation of these findings into urological practice remains a matter of controversial discussion...
  5. doi [Secondary and tertiary prevention of urological tumors]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763, Fürth, Deutschland
    Urologe A 50:1283-7. 2011
    ..The authors recommend that the scientifically neglected field of tertiary prevention of urological tumors should in future be included as a core factor of scientific investigations...
  6. doi [Primary prevention of urologic tumors: prostate cancer]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763, Fürth, Deutschland
    Urologe A 50:1271-2, 1274-5. 2011
    ..Converting this result into urologic practice remains the topic of extensive controversy...
  7. doi [Role of immunocytology in the evaluation of patients with painless gross hematuria]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763, Fürth, Germany
    Urologe A 49:741-6. 2010
    ..In this prospective study the role of immunocytology in the evaluation of patients with gross hematuria was investigated...
  8. doi [Risks and prevention of prostate cancer. Commentary on the new S3 guideline]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth
    Urologe A 49:233-7. 2010
    ..New findings of prospective studies on chemoprevention were incorporated into a statement. Since 5-alpha-reductase inhibitors have not yet been approved for prevention of prostate cancer, no recommendation was given...
  9. ncbi Immunocytology in the assessment of patients with asymptomatic hematuria
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth, Germany
    World J Urol 26:31-7. 2008
    ..In patients with microhematuria immunocytology could be used to select for patients at risk for urothelial cancer and thus spare negative patients from further examinations...
  10. ncbi [Analyses of the role of immunocytology in the differential diagnosis of patients with asymptomatic microhematuria]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763, Fürth
    Urologe A 47:190-4. 2008
    ..In this prospective study the role of immunocytology in the assessment microhematuria was studied...
  11. ncbi Immunocytology in the assessment of patients with painless gross haematuria
    Bernd Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, D 90763 Fürth, Germany
    BJU Int 101:455-8. 2008
    ..Due to the high prevalence of urothelial cancer in this population, a thorough assessment is mandatory to identify all patients with tumours...
  12. ncbi [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth
    Urologe A 46:1364, 1366-8, 1370. 2007
    ..Future research must now aim at defining high-risk groups specifically profiting from chemoprevention with a 5-alpha-reductase inhibitor...
  13. ncbi Tumorgenesis due to papillomavirus infection was first demonstrated in rabbits and cattle early last century
    Bernd Jürgen Schmitz-Drager
    Eur Urol 52:468-9. 2007
  14. ncbi [Chemoprevention of prostate cancer. Current status]
    B J Schmitz-Dräger
    Urologie, EuromedClinic, Europa Allee 1, 90763 Fürth, Germany
    Urologe A 46:611-5. 2007
    ..Considering the high incidence and the fact that the diagnosis of prostate cancer has serious impact on the future life of the respective individuals further scientific evaluation of chemoprevention of prostate cancer is mandatory...
  15. ncbi Immunocytology in the assessment of patients with asymptomatic microhaematuria
    Bernd J Schmitz-Drager
    Urologie, EuromedClinic, Fürth, Germany
    Eur Urol 51:1582-8; discussion 1588. 2007
    ..Discrimination between malignant and nonmalignant conditions remains the key problem in assessing microhaematuria. This prospective study investigated the role of immunocytology in the evaluation of patients with microhaematuria...
  16. ncbi Nutrition and prostate cancer
    B J Schmitz-Dräger
    Urology, EuromedClinic, Fürth, Germany
    Urol Int 67:1-11. 2001
    ..However, regarding the potential relevance of chemoprevention on public health, further efforts to identify nutritional factors affecting prostate cancer growth are warranted...
  17. ncbi p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?
    B J Schmitz-Dräger
    Urology, Euromed Clinic, Fürth, Germany
    Eur Urol 38:691-9;discussion 700. 2000
    ..Furthermore, putative reasons for the conflicting results should be defined as a basis for future research...
  18. ncbi [Taking stock after 400 days: the effects on ambulatory care from a medical point of view]
    Lothar Weissbach
    Urologische Partnerschaft EuromedClinic Fürth
    Z Arztl Fortbild Qualitatssich 100:40-3; discussion 44. 2006
    ..Advantages and disadvantages for the parties involved are explained. Integrated care might be one of the contributions needed to effect the necessary structural changes of the German healthcare system...